A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers

Adam S. Feldman, Vinata Lokeshwar, Daniel W. Lin

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

The past 25 years have witnessed an explosion of investigative attempts to identify clinically useful biomarkers which can have meaningful impacts for patients with urologic cancers. However, in spite of the enormous amount of research aiming to identify markers with the hope of impacting patient care, only a handful have proven to have true clinical utility. Improvements in targeted imaging, pan-omics evaluation, and genetic sequencing at the tissue and single-cell levels have yielded many potential targets for continued biomarker investigation. This article, as one in this series for the 25th Anniversary Issue of Urologic Oncology: Seminars and Original Investigations, serves to give a perspective on our progress and failures over the past quarter-century in our highest volume urologic cancers: prostate, bladder, and kidney cancers.

Original languageEnglish (US)
Pages (from-to)602-617
Number of pages16
JournalUrologic Oncology: Seminars and Original Investigations
Volume39
Issue number9
DOIs
StatePublished - Sep 2021
Externally publishedYes

Keywords

  • Biomarker
  • Bladder
  • Cancer
  • Genomics
  • Kidney
  • Prostate

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint

Dive into the research topics of 'A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers'. Together they form a unique fingerprint.

Cite this